SSY Group (HKG:2005) obtained drug production and registration approval for Ozagrel Sodium Injection from China's National Medical Products Administration.
The move came as the drug was regarded as having passed the regulator's consistency evaluation, according to a Tuesday Hong Kong bourse filing.
The product is mainly used to treat acute thrombotic cerebral infarction and motor dysfunction associated with cerebral infarction.